These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33290989)

  • 21. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional Characteristics of
    Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
    Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
    [No Abstract]   [Full Text] [Related]  

  • 25. Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q.
    Zou H; Li C; Wanggou S; Li X
    J Cancer; 2020; 11(15):4297-4307. PubMed ID: 32489448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.
    Wijnenga MMJ; French PJ; Dubbink HJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Fleischeuer R; Dirven CMF; Vincent AJPE; van den Bent MJ
    J Neurooncol; 2018 Sep; 139(2):349-357. PubMed ID: 29663171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis Analysis and Validation of m
    Lin S; Xu H; Zhang A; Ni Y; Xu Y; Meng T; Wang M; Lou M
    Front Oncol; 2020; 10():541401. PubMed ID: 33123464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying α-KG-dependent prognostic signature for lower-grade glioma based on transcriptome profiles.
    Zhang T; Yuan L; Sheng M; Chen Y; Wang J; Lan Q
    Front Oncol; 2022; 12():840394. PubMed ID: 35965532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
    Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
    J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
    Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDH mutation in glioma: new insights and promises for the future.
    Turkalp Z; Karamchandani J; Das S
    JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.
    Xiao G; Gao X; Li L; Liu C; Liu Z; Peng H; Xia X; Yi X; Zhou R
    J Oncol; 2021; 2021():3766685. PubMed ID: 34961815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.